Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting

Current Medical Research and Opinion

Volumn 26, Issue 1, 2010, Pages 9-15

  Nichols, Gregory A ^a   Gandra, Shravanthi R ^b   Chiou, Chiun Fang ^b   Anthony, Mary S ^b   Alexander Bridges, Maria ^b   Brown, Jonathan B ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b AMGEN INC   (United States)

Author keywords

Glycemic control; Guidelines; Insulin; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; DRUG DOSE TITRATION; EDEMA; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME; WEIGHT GAIN; GLUCOSE BLOOD LEVEL; HEALTH INSURANCE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED;

EID: 77649213381     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903417679     Document Type: Article

References (28)

1. UKPDS Group. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies UKPDS 49. JAMA 1999;281:2005-12
2. De Witt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: a scientific review. JAMA 2003;289:2254-64 (Pubitemid 37430194)
3. Dailey III GE. Early insulin: an important therapeutic strategy. Diabetes Care 2005;28:220-1 (Pubitemid 40095805)
4. Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J 2007;100:164-74 (Pubitemid 46213760)
5. Davidson MB. Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care 2005;28:222-4 (Pubitemid 40095806)
6. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203
7. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005; 28:2543-5 (Pubitemid 41384310)
8. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-9 (Pubitemid 43951158)
9. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-40 (Pubitemid 38857422)
10. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control. J Gen Intern Med 2007; 22:453-8 (Pubitemid 46941217)
11. van Avendonk MJ, Rutten GE. Insulin therapy in type 2 diabetes: what is the evidence? Diabetes Obes Metab 2009; epub ahead of print
12. Hirsch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005;23:78-86 (Pubitemid 40965048)
13. Tibaldi J. Initiating and intensifying insulin therapy in type 2 diabetes mellitus. Am J Med 2008;121:S20-9 (Pubitemid 351726335)
14. Vinik A. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 2007; 29:1236-53 (Pubitemid 351172224)
15. Horton ES. Defining the role of basal and prandial insulin for optimal glycemic control. J Am Coll Cardiol 2009;53:S21-7
16. Spellman CW. Insulin therapy for maximal glycemic control in type 2 diabetes mellitus. J Am Osteopath Assoc 2007;107:260-9 (Pubitemid 47281328)
17. Alexander GC, Sehgal NL, Moloney RM, et al. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168: 2088-94
18. Brown JB, Nichols GA, Glauber HS. Case-control study of 10 years of comprehensive diabetes care. West J Med 2000;172:85-90
19. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:1963-72
20. CDC Diabetes Cost-Effectiveness Study Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-51
21. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357:1716-30 (Pubitemid 350005153)
22. Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:1653-9 (Pubitemid 32681147)
23. Akram K, Pedersen-Bjergaard U, Borch-Johnsen K, et al. Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: A literature survey. J Diabetes Complications 2006;20:402-8 (Pubitemid 44740218)
24. Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycemic therapies. Diabetes Obes Metab 2007;9: 96-102 (Pubitemid 44921047)
25. UKPDS Group. UKPDS 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165-75
26. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358: 2545-59
27. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-72
28. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360: 129-39